Anti-inflammatory synergy of MEN16132, a kinin B 2 receptor antagonist, and dexamethasone in carrageenan-induced knee joint arthritis in rats

British Journal of Pharmacology

Volumn 161, Issue 7, 2010, Pages 1616-1627

  Valenti, C ^a   Giuliani, S ^a   Cialdai, C ^a   Tramontana, M ^a   Maggi, C A ^a  

^a Menarini Ricerche SpA   (Italy)

Author keywords

Arthritis; B 2 receptor antagonist; Bradykinin; Carrageenan; Dexamethasone; Lipopolysaccharide; MEN16132; Steroidal anti inflammatory drug; Synergism

Indexed keywords

4 AMINO 5 [4 [4 [2,4 DICHLORO 3 (2,4 DIMETHYL 8 QUINOLYLOXYMETHYL)PHENYLSULFONAMIDO]TETRAHYDRO 2H 4 PYRANYLCARBONYL]PIPERAZINO] 5 OXOPENTYL(TRIMETHYL)AMMONIUM CHLORIDE; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONIST; CARRAGEENAN; DEXAMETHASONE; DEXKETOPROFEN; HYDROCORTISONE SODIUM SUCCINATE; ICATIBANT; KALLIKREIN; LIPOPOLYSACCHARIDE; MEN 16132; MYELOPEROXIDASE; PREKALLIKREIN; TISSUE KALLIKREIN; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; EDEMA; ENZYME ACTIVITY; KNEE ARTHRITIS; KNEE PAIN; MEDIATOR RELEASE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; RAT; SYNOVIUM;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; BRADYKININ; CARRAGEENAN; DEXAMETHASONE; DRUG SYNERGISM; INJECTIONS, INTRA-ARTICULAR; KALLIKREINS; KNEE JOINT; LIPOPOLYSACCHARIDES; MALE; ORNITHINE; PEROXIDASE; RATS; RATS, WISTAR; RECEPTOR, BRADYKININ B2; SULFONAMIDES;

EID: 78149399009     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00995.x     Document Type: Article

References (42)

1. Alexander SPH, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC). 4th edn. Br J Pharmacol 158 (Suppl. 1): S1-S254.
2. Bathon JM, Chilton FH, Hubbard WC, Towns MC, Solan NJ, Proud D (1996). Mechanisms of prostanoid synthesis in human synovial cells: cytokine-peptide synergism. Inflammation 20: 537-554.
3. Bijlsma JW, Van Everdingen AA, Huisman M, De Nijs RN, Jacobs JW (2002). Glucocorticoids in rheumatoid arthritis: effects on erosions and bone. Ann N Y Acad Sci 966: 82-90.
4. Brechter AB, Lerner UH (2002). Characterization of bradykinin receptors in a human osteoblastic cell line. Regul Pept 103: 39-51.
5. Brechter AB, Lerner UH (2007). Bradykinin potentiates cytokine-induced prostaglandin biosynthesis in osteoblasts by enhanced expression of cyclooxygenase 2, resulting in increased RANKL expression. Arthritis Rheum 56: 910-923.
6. Burch RM, Tiffany CW (1989). Tumor necrosis factor causes amplification of arachidonic acid metabolism in response to interleukin 1, bradykinin, and other agonists. J Cell Physiol 141: 85-89.
7. Cambridge H, Brain SD (1995). Mechanism of bradykinin-induced plasma extravasation in the rat knee joint. Br J Pharmacol 115: 641-647.
8. Cassim B, Shaw OM, Mazur M, Misso NL, Naran A, Laglands DR et al. (2009). Kallikreins, kininogens and kinin receptors on circulating and synovial neutrophils: role in kinin generation in rheumatoid arthritis. Rheumatology 48: 490-496.
9. Cheng JK, Ji RR (2008). Intracellular signaling in primary sensory neurons and persistent pain. Neurochem Res 33: 1970-1978.
10. Chou TC, Talalay P (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
11. 2 receptor antagonist, on nociceptive response in monosodium iodoacetate-induced experimental osteoarthritis in rats. J Pharmacol Exp Ther 331: 1025-1032.
12. Colman RW (2006). Regulation of angiogenesis by the kallikrein-kinin system. Curr Pharm Des 12: 2599-2607.
13. 2 receptor. In vitro pharmacology and molecular characterization. Eur J Pharmacol 528: 7-16.
14. Cunha FQ, Poole S, Lorenzetti BB, Ferreira SH (1992). The pivotal role of tumour necrosis factor α in the development of inflammatory hyperalgesia. Br J Pharmacol 107: 660-664.
15. Damas J, Remacle-Volon G (1992). Influence of a long-acting bradykinin antagonist, Hoe 140, on some acute inflammatory reactions in the rat. Eur J Pharmacol 211: 81-86.
16. Davies GE, Holman G, Johnston TP, Lowe JS (1966). Studies on kallikrein: failure of some anti-inflammatory drugs to affect release of kinin. Br J Pharmacol Chemother 28: 212-217.
17. Dray A, Read SJ (2007). Arthritis and pain. Future targets to control osteoarthritis pain. Arthritis Res Ther 9: 212.
18. Earp JC, DuBois DC, Molano DS, Pyszczynski NA, Almon RR, Jusko WJ (2008). Modeling corticosteroid effects in a rat model of rheumatoid arthritis II: mechanistic pharmacodynamic model for dexamethasone effects in Lewis rats with collagen-induced arthritis. J Pharmacol Exp Ther 326: 546-554.
19. Ferreira SH, Lorenzetti BB, Poole S (1993). Bradykinin initiates cytokine-mediated inflammatory hyperalgesia. Br J Pharmacol 110: 1227-1231.
20. Francischi JN, Chaves CT, Moura ACL, Lima AS, Rocha OA, Ferreira-Alves DL et al. (2002). Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. Br J Pharmacol 137: 837-844.
21. Geiger R, Miska W (1988). Human tissue kallikrein. Methods Enzymol 163: 120-115.
22. Jenzano JW, Coffey JC, Heizer WD, Lundblad RL, Scicli AG (1988). The assay of glandular kallikrein and prekallikrein in human mixed saliva. Arch Oral Biol 33: 641-644.
23. Kamal AM, Flower RJ, Perretti M (2005). An overview of the effects of annexin 1 on cells involved in the inflammatory process. Mem Inst Oswaldo Cruz 100: 39-48.
24. Leeb-Lundberg LMF, Marceau F, Müller-Esterl W, Pettibone DJ, Zuraw BL (2005). Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 57: 27-77.
25. Lo EJ, Green PG, Miao FJ, Relchling DB, Levine JD (1999). Bradykinin-induced neurogenic migration of neutrophils into the rat knee joint. Neuroreport 10: 3821-3824.
26. 2 receptor antagonist, FR173657, on plasma exudation in rat carrageenin-induced pleurisy. Br J Pharmacol 121: 723-730.
27. Meini S, Maggi CA (2008). Knee osteoarthritis: a role for bradykinin? Inflamm Res 57: 351-361.
28. 2 receptor antagonism in human knee synoviocytes and chondrocytes. Osteoarthritis Cartilage 16 (Suppl. 4): S188.
29. Nishimura M, Segami N, Kaneyama K, Suzuki T, Miyamaru M (2002). Relationships between pain-related mediators and both synovitis and joint pain in patients with internal derangements and osteoarthritis of the temporomandibular joint. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 94: 328-332.
30. Pawlak M, Borkiewicz P, Podgòrski T, Schmidt RF (2008). The activity of fine afferent nerve fibres of the rat knee joint and their modulation by inflammatory mediators. Ortop Traumatol Rehabil 10: 63-74.
31. 2 receptors, tumor necrosis factor α and inflammatory hyperalgesia. Br J Pharmacol 126: 649-656.
32. Rahman MM, Bhoola KD, Elson CJ, Lemon M, Dieppe PA (1995). Identification and functional importance of plasma kallikrein in the synovial fluids of patients with rheumatoid, psoriatic, and osteoarthritis. Ann Rheum Dis 54: 345-350.
33. Schneider T, Issekutz AC (1996). Quantitation of eosinophil and neutrophil infiltration into rat lung by specific assays for eosinophil peroxidase and myeloperoxidase. Application in a Brown Norway rat model of allergic pulmonary inflammation. J Immunol Methods 198: 1-14.
34. Sharma JN, Buchanan WW (1994). Pathogenic responses of bradykinin system in chronic inflammatory rheumatoid disease. Exp Toxicol Pathol 46: 421-433.
35. Sharma JN, Wirth KJ (1996). Inhibition of rats adjuvant arthritis by a bradykinin antagonist Hoe 140 and its influence on kallikreins. Gen Pharmacol 27: 133-136.
36. Song IH, Althoff CE, Hermann K, Scheel AK, Knetsch T, Burmester G et al. (2008). Contrast-enhanced ultrasound in monitoring the efficacy of a bradykinin receptor-2 antagonist in painful knee osteoarthritis compared to magnetic resonance imaging. Ann Rheum Dis 68: 75-83.
37. Sorbera LA, Fernandez-Forner D, Bayes M (2006). Icatibant acetate. Drugs Future 31: 101-106.
38. Tonussi CR, Ferreira SH (1999). Tumor necrosis factor-α mediates carrageenin-induced knee-joint incapacitation and also triggers overt nociception in previously inflamed rat knee-joints. Pain 82: 81-87.
39. 2 receptor antagonist: in vivo activity on bradykinin-induced bronchoconstriction and nasal mucosa microvascular leakage in anesthetized guinea pigs. J Pharmacol Exp Ther 315: 616-623.
40. Yang Y, Hutchinson P, Morand EF (1999). Inhibitory effect of annexin I on synovial inflammation in rat adjuvant arthritis. Arthritis Rheum 42: 1538-1544.
41. Zhang Y, Adner M, Cardell LO (2005). Glucocorticoids suppress transcriptional up-regulation of bradykinin receptors in a murine in vitro model of chronic airway inflammation. Clin Exp Allergy 35: 531-538.
42. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N et al. (2007). OARSI recommendations for the management of hip and knee osteoarthritis, Part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 15: 981-1000.